EDAP TMS (EDAP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
EDAP TMS has announced significant findings from the HIFI study, highlighting the effectiveness of its Focal One robotic HIFU technology in treating localized prostate cancer. The study, published in European Urology, shows Focal One as a less invasive alternative to surgery with better outcomes in urinary continence and erectile function. These results could increase the adoption of Focal One as a primary treatment option, offering a promising advancement in prostate cancer care.
For further insights into EDAP stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Can MicroStrategy Stock Reach Around $1,000? Here’s What This Investor Expects
- Bank of America Chimes in on Intel Stock, Warning of a Bumpy Road Ahead
- ‘Don’t Jump on the Bandwagon,’ Says J.P. Morgan About Super Micro Computer Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
